Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 511.5 SEK -1.16% Market Closed
Market Cap: 30.1B SEK

EV/EBITDA
Enterprise Value to EBITDA

42.6
Current
66.3
Median
12.6
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
42.6
=
Enterprise Value
27.5B SEK
/
EBITDA
646m SEK
Market Cap EV/EBITDA
SE
Camurus AB
STO:CAMX
30.3B SEK 42.6
US
Eli Lilly and Co
NYSE:LLY
687.3B USD 33.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
368.7B USD 12.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 13.6
CH
Roche Holding AG
SIX:ROG
207.5B CHF 9.4
CH
Novartis AG
SIX:NOVN
183.5B CHF 10.2
UK
AstraZeneca PLC
LSE:AZN
162.6B GBP 130.3
US
Merck & Co Inc
NYSE:MRK
195.2B USD 8.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
134.2B USD 7.4
EBITDA Growth EV/EBITDA to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBITDA: 397.7
42.6
82%
0.5
US
Eli Lilly and Co
NYSE:LLY
33.3
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
10%
13
US
Merck & Co Inc
NYSE:MRK
8.4
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
24.9
2-Years Forward
EV/EBITDA
14
3-Years Forward
EV/EBITDA
9.4